Skip to content
Menu

Stoke Therapeutics, Inc. STOK

Full chart Compare
Set alert

Price alert · STOK

All alert types
26.81 USD -0.12 (-0.45%)

Regular-session close

27.40 +0.59 +2.20%

After hours · Nov 20, 4:34 PM ET

25.94 Day range 27.78
22.50 52-week range 38.35
YTD
-15.53%
1 year
-4.01%

5D -0.77 (-2.80%)

2627ThuFriMonTueWed26.69
Market cap
1.75B
Revenue (ttm)
28.21M
EPS (ttm)
-3.81
Shares out
65.41M
Forward P/E
-6.56
YTD return
-15.53%
1-year return
-4.01%
50-day average
26.20
200-day average
30.69
Enterprise value
1.44B
Volume
615.75K
Avg volume
1.03M
Open
26.35
Previous close
26.93
Day's range
25.94 – 27.78
52-week range
22.50 – 38.35
Beta
1.38
Analysts
Strong Buy
Price target
46.38 (+73.0%)
Earnings date
Mar 15, 2027

Key statistics

Price / sales
62.16
Price / book
4.93
Revenue growth
5.90%
Free cash flow
-125.55M
Total cash
319.19M
Total debt
1.92M
Return on equity
-73.62%
Short % of float
17.02%

Fundamental scorecard

5 of 25 checks passed on STOK’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
STOK Revenue — quarterly 11.26M
STOK Net income — quarterly -73.64M
STOK EPS — quarterly -1.08

Earnings

STOK recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 15, 2027Mar 30, 2027-1.15———
Oct 29, 2026Sep 30, 2026-0.92914-1.08-0.15-16.24%
Aug 3, 2026Jun 30, 2026-0.795-0.93-0.13-16.98%
May 7, 2026Mar 31, 2026-0.80-0.79+0.01+1.25%
Mar 16, 2026Dec 31, 2025-0.75-0.97-0.22-29.33%
Nov 4, 2025Sep 30, 2025-0.54-0.65-0.11-20.37%

Upgrades / downgrades

STOK analyst upgrades and downgrades
DateFirmActionFromTo
Aug 4, 2026GuggenheimreitBuyBuy
Aug 4, 2026WedbushmainOutperformOutperform
Aug 4, 2026Canaccord GenuitymainBuyBuy
Aug 4, 2026Chardan CapitalmainBuyBuy
Jul 13, 2026Goldman Sachsinit—Buy
May 11, 2026BTIGreitBuyBuy

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on STOK — it syncs with the Stock Master app.

Insider holders

STOK insider holders
InsiderRelationLatest transactionDateShares held
ALLAN JONATHANGeneral CounselSaleAug 17, 202621,225
HOITT JASONOfficerSaleMar 17, 202610,276
KAYE EDWARD MDirectorSaleAug 17, 2026124,557
KRAINER ADRIAN RDirectorSaleMar 9, 2026283,302
LEGGETT THOMASChief Financial OfficerSaleMar 17, 202610,172
LEVIN ARTHUR A.DirectorSaleMar 12, 202622,216

Institution ownership

STOK institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.71%6,347,831170.19MSep 29, 2026
RTW Investments LP8.60%5,623,525150.77MSep 29, 2026
FMR, LLC7.65%5,000,952134.08MSep 29, 2026
Wellington Management Group, LLP7.16%4,681,855125.52MSep 29, 2026
Lynx1 Capital Management Lp5.96%3,896,169104.46MSep 29, 2026
Redmile Group, LLC5.92%3,869,028103.73MSep 29, 2026

Fund ownership

STOK fund ownership
Holder% heldSharesValueReported
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund3.46%2,260,55060.61MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.88%1,884,64750.53MJun 29, 2026
Fidelity Select Portfolios-Select Biotechnology Portfolio2.28%1,490,48139.96MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.18%1,426,54938.25MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.01%1,311,56735.16MSep 29, 2026
T. Rowe Price New Horizons Fund, Inc.1.11%729,20119.55MJun 29, 2026